Revolutionising Communication: Neuroprosthetic System Transforms Neural Activity into Speech for Paralyzed Individuals

By Michael Awood

August 30, 2023

In a pioneering study, researchers have created a multimodal speech neuroprosthetic system that could potentially restore full communication to those with severe paralysis. This innovative system decodes and converts neural activity into text, speech audio, and facial-avatar animation using high-density surface recordings of the speech cortex.

The system’s capabilities were demonstrated by a 47-year-old woman with severe limb and vocal paralysis caused by a basilar artery brainstem stroke. Despite her inability to vocalize or type, she achieved a median rate of 78 words per minute with a 25% word error rate using the neuroprosthetic system, significantly surpassing her previous rate of 14 words per minute using a commercial head-tracking system. The researchers even synthesized speech audio in her pre-injury voice and created a personalized avatar capable of realistic and interpretable speech and non-verbal facial gestures.

The neuroprosthetic system showed high performance within two weeks of training, outperforming previous brain-computer interfaces by four times in communication speed and twenty times in vocabulary size.

The study recognizes the need for further validation in other individuals with varying types of paralysis, as it is a proof-of-concept study based on a single patient. Future developments in electrode interfaces and real-time closed-loop feedback during decoding could improve user engagement, model performance, and neural entrainment.

This breakthrough offers immense potential for those living with paralysis. Improved communication through evolving technology could significantly enhance their quality of life by enabling meaningful interpersonal interactions.

The study participant expressed how this technology could enhance her daily life by improving expressivity, independence, and productivity. The ultimate goal is to integrate this technology seamlessly into real-world applications, offering hope to those living with speech loss due to severe paralysis.

Reference url

Recent Posts

oral GLP-1 medication
    

Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron Succeeds in Phase 3

🌟 Ready for a breakthrough in diabetes management?

Eli Lilly’s oral GLP-1 medication, orforglipron, has completed a successful Phase 3 trial, showing remarkable efficacy in lowering A1C levels and promoting substantial weight loss. As the first oral small molecule GLP-1 receptor agonist, it offers a promising alternative to conventional injectable treatments, potentially improving patient adherence and access.

Dive into the details of this exciting development and what it means for the future of diabetes care!

#SyenzaNews #HealthTech #Innovation #Pharmaceuticals

pediatric thyroid cancer risk
    

Environmental Exposures and Pediatric Thyroid Cancer Risk: Key Findings from a California Study

🌟 Are we overlooking environmental risks in pediatric cancer?

Recent research highlights a troubling link between perinatal exposure to PM2.5 and outdoor artificial light and the increased risk of pediatric thyroid cancer. This pivotal study sheds light on how environmental factors play a critical role in childhood health, particularly among vulnerable populations.

Dive into this important discussion on how addressing these environmental exposures may reduce pediatric thyroid cancer and improve health outcomes for future generations.

#SyenzaNews #EnvironmentalHealth #HealthPolicy #Innovation

capivasertib cost-effectiveness
      

Capivasertib Cost-Effectiveness in Advanced Breast Cancer

💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?

A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.

Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.

#SyenzaNews #HealthEconomics #costeffectiveness #oncology

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.